{"pmid":32488837,"pmcid":"PMC7266418","title":"Possible long-term endocrine-metabolic complications in COVID-19: lesson from the SARS model.","text":["Possible long-term endocrine-metabolic complications in COVID-19: lesson from the SARS model.","The outbreak of coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is centralizing the interest of the scientific world. In the next months, long-term consequences on the endocrine system may arise following COVID-19. In this article, we hypothesized the effects of SARS-CoV-2 taking into account what learned from the severe acute respiratory syndrome coronavirus (SARS-CoV) that caused SARS in 2003.","Endocrine","Mongioi, Laura M","Barbagallo, Federica","Condorelli, Rosita A","Cannarella, Rossella","Aversa, Antonio","La Vignera, Sandro","Calogero, Aldo E","32488837"],"abstract":["The outbreak of coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is centralizing the interest of the scientific world. In the next months, long-term consequences on the endocrine system may arise following COVID-19. In this article, we hypothesized the effects of SARS-CoV-2 taking into account what learned from the severe acute respiratory syndrome coronavirus (SARS-CoV) that caused SARS in 2003."],"journal":"Endocrine","authors":["Mongioi, Laura M","Barbagallo, Federica","Condorelli, Rosita A","Cannarella, Rossella","Aversa, Antonio","La Vignera, Sandro","Calogero, Aldo E"],"date":"2020-06-04T11:00:00Z","year":2020,"_id":"32488837","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.1007/s12020-020-02349-7","keywords":["adrenal glands","covid-19","diabetes","obesity","pituitary gland","sars"],"topics":["Mechanism"],"weight":1,"_version_":1668892169284354049,"score":9.490897,"similar":[{"pmid":32451846,"pmcid":"PMC7247778","title":"Does SARS-CoV-2 infection cause chronic neurological complications?","text":["Does SARS-CoV-2 infection cause chronic neurological complications?","The current pandemic caused by severe acute respiratory syndrome coronavirus (SARS-CoV)-2 has created an unparalleled health crisis. Besides the acute respiratory infection, CoVs are neuroinvasive causing additional inflammation and neurodegeneration. This is likely also true of SARS-CoV-2 given reports of neurological manifestations in coronavirus disease 2019 (COVID-19) positive patients. Older adults > 65 years of age constitute a high-risk group prone to severe infection and death. Despite the higher mortality rate, a majority of cases are expected to recover and survive from this viral outbreak. But, the long-term consequences of SARS-CoV-2 neuroinfection are unknown. We discuss these potential chronic changes to the central nervous system (CNS) in relation to accelerated brain aging and age-related neurodegenerative disorders.","Geroscience","Hascup, Erin R","Hascup, Kevin N","32451846"],"abstract":["The current pandemic caused by severe acute respiratory syndrome coronavirus (SARS-CoV)-2 has created an unparalleled health crisis. Besides the acute respiratory infection, CoVs are neuroinvasive causing additional inflammation and neurodegeneration. This is likely also true of SARS-CoV-2 given reports of neurological manifestations in coronavirus disease 2019 (COVID-19) positive patients. Older adults > 65 years of age constitute a high-risk group prone to severe infection and death. Despite the higher mortality rate, a majority of cases are expected to recover and survive from this viral outbreak. But, the long-term consequences of SARS-CoV-2 neuroinfection are unknown. We discuss these potential chronic changes to the central nervous system (CNS) in relation to accelerated brain aging and age-related neurodegenerative disorders."],"journal":"Geroscience","authors":["Hascup, Erin R","Hascup, Kevin N"],"date":"2020-05-27T11:00:00Z","year":2020,"_id":"32451846","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.1007/s11357-020-00207-y","keywords":["aging","alzheimer's disease","covid-19","cellular senescence","neurodegeneration","neurotropism"],"topics":["Mechanism"],"weight":1,"_version_":1667983494534397953,"score":113.79327},{"pmid":32498691,"title":"Immediate and long-term consequences of COVID-19 infections for the development of neurological disease.","text":["Immediate and long-term consequences of COVID-19 infections for the development of neurological disease.","Increasing evidence suggests that infection with Sars-CoV-2 causes neurological deficits in a substantial proportion of affected patients. While these symptoms arise acutely during the course of infection, less is known about the possible long-term consequences for the brain. Severely affected COVID-19 cases experience high levels of proinflammatory cytokines and acute respiratory dysfunction and often require assisted ventilation. All these factors have been suggested to cause cognitive decline. Pathogenetically, this may result from direct negative effects of the immune reaction, acceleration or aggravation of pre-existing cognitive deficits, or de novo induction of a neurodegenerative disease. This article summarizes the current understanding of neurological symptoms of COVID-19 and hypothesizes that affected patients may be at higher risk of developing cognitive decline after overcoming the primary COVID-19 infection. A structured prospective evaluation should analyze the likelihood, time course, and severity of cognitive impairment following the COVID-19 pandemic.","Alzheimers Res Ther","Heneka, Michael T","Golenbock, Douglas","Latz, Eicke","Morgan, Dave","Brown, Robert","32498691"],"abstract":["Increasing evidence suggests that infection with Sars-CoV-2 causes neurological deficits in a substantial proportion of affected patients. While these symptoms arise acutely during the course of infection, less is known about the possible long-term consequences for the brain. Severely affected COVID-19 cases experience high levels of proinflammatory cytokines and acute respiratory dysfunction and often require assisted ventilation. All these factors have been suggested to cause cognitive decline. Pathogenetically, this may result from direct negative effects of the immune reaction, acceleration or aggravation of pre-existing cognitive deficits, or de novo induction of a neurodegenerative disease. This article summarizes the current understanding of neurological symptoms of COVID-19 and hypothesizes that affected patients may be at higher risk of developing cognitive decline after overcoming the primary COVID-19 infection. A structured prospective evaluation should analyze the likelihood, time course, and severity of cognitive impairment following the COVID-19 pandemic."],"journal":"Alzheimers Res Ther","authors":["Heneka, Michael T","Golenbock, Douglas","Latz, Eicke","Morgan, Dave","Brown, Robert"],"date":"2020-06-06T11:00:00Z","year":2020,"_id":"32498691","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.1186/s13195-020-00640-3","keywords":["cognition","cytokine","decline","nlrp3 inflammasome","neurodegeneration","neuroinflammation","systemic inflammation"],"topics":["Treatment","Diagnosis"],"weight":1,"_version_":1668804508697755648,"score":113.059105},{"pmid":32417124,"title":"COVID-19, SARS and MERS: A neurological perspective.","text":["COVID-19, SARS and MERS: A neurological perspective.","Central to COVID-19 pathophysiology is an acute respiratory infection primarily manifesting as pneumonia. Two months into the COVID-19 outbreak, however, a retrospective study in China involving more than 200 participants revealed a neurological component to COVID-19 in a subset of patients. The observed symptoms, the cause of which remains unclear, included impaired consciousness, skeletal muscle injury and acute cerebrovascular disease, and appeared more frequently in severe disease. Since then, findings from several studies have hinted at various possible neurological outcomes in COVID-19 patients. Here, we review the historical association between neurological complications and highly pathological coronaviruses including SARS-CoV, MERS-CoV and SARS-CoV-2. We draw from evidence derived from past coronavirus outbreaks, noting the similarities and differences between SARS and MERS, and the current COVID-19 pandemic. We end by briefly discussing possible mechanisms by which the coronavirus impacts on the human nervous system, as well as neurology-specific considerations that arise from the repercussions of COVID-19.","J Clin Neurosci","Ng Kee Kwong, Koy Chong","Mehta, Puja R","Shukla, Garima","Mehta, Arpan R","32417124"],"abstract":["Central to COVID-19 pathophysiology is an acute respiratory infection primarily manifesting as pneumonia. Two months into the COVID-19 outbreak, however, a retrospective study in China involving more than 200 participants revealed a neurological component to COVID-19 in a subset of patients. The observed symptoms, the cause of which remains unclear, included impaired consciousness, skeletal muscle injury and acute cerebrovascular disease, and appeared more frequently in severe disease. Since then, findings from several studies have hinted at various possible neurological outcomes in COVID-19 patients. Here, we review the historical association between neurological complications and highly pathological coronaviruses including SARS-CoV, MERS-CoV and SARS-CoV-2. We draw from evidence derived from past coronavirus outbreaks, noting the similarities and differences between SARS and MERS, and the current COVID-19 pandemic. We end by briefly discussing possible mechanisms by which the coronavirus impacts on the human nervous system, as well as neurology-specific considerations that arise from the repercussions of COVID-19."],"journal":"J Clin Neurosci","authors":["Ng Kee Kwong, Koy Chong","Mehta, Puja R","Shukla, Garima","Mehta, Arpan R"],"date":"2020-05-18T11:00:00Z","year":2020,"_id":"32417124","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1016/j.jocn.2020.04.124","keywords":["covid-19","coronavirus","mers","neurology","neurotropism","sars"],"locations":["China"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Mechanism","Diagnosis"],"weight":1,"_version_":1667058206727208960,"score":106.383156},{"pmid":32477373,"pmcid":"PMC7235419","title":"Implications of COVID-19 Outbreak on Immune Therapies in Multiple Sclerosis Patients-Lessons Learned From SARS and MERS.","text":["Implications of COVID-19 Outbreak on Immune Therapies in Multiple Sclerosis Patients-Lessons Learned From SARS and MERS.","Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) pandemic keeps the world in suspense. In addition to the fundamental challenges for the health care system, the individual departments must decide how to deal with patients at risk. Neurologists are confronted with the question, how they should advise their patients regarding immunosuppressive treatment. In particular, the large number of different disease-modifying therapies (DMTs) in the treatment of neuroimmunological diseases such as multiple sclerosis poses a challenge. To a limited extent, it might be useful to transfer knowledge from previous SARS- and Middle East respiratory syndrome (MERS) coronavirus outbreaks in 2002/2003 and 2012 to the current situation. Overall, immunosuppressive therapy does neither seem to have a major impact on infection with SARS- and MERS-CoV nor does it seem to lead to a severe disease course in many cases. Considering the immunological responses against infections with novel coronaviruses in humans, interferons, glatiramer acetate, and teriflunomide appear to be safe. As lymphopenia seems to be associated with a more severe disease course, all DMTs causing lymphopenia, such as cladribine, alemtuzumab, and dimethyl fumarate, need to be reviewed more thoroughly. As they are, in general, associated with a higher risk of infection, depleting anti-CD20 antibodies may be problematic drugs. However, it has to be differentiated between the depletion phase and the phase of immune reconstitution. In summary, previous coronavirus outbreaks have not shown an increased risk for immunocompromised patients. Patients with severe neuroimmunological diseases should be kept from hasty discontinuation of immunotherapy.","Front Immunol","Mohn, Nora","Pul, Refik","Kleinschnitz, Christoph","Pruss, Harald","Witte, Torsten","Stangel, Martin","Skripuletz, Thomas","32477373"],"abstract":["Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) pandemic keeps the world in suspense. In addition to the fundamental challenges for the health care system, the individual departments must decide how to deal with patients at risk. Neurologists are confronted with the question, how they should advise their patients regarding immunosuppressive treatment. In particular, the large number of different disease-modifying therapies (DMTs) in the treatment of neuroimmunological diseases such as multiple sclerosis poses a challenge. To a limited extent, it might be useful to transfer knowledge from previous SARS- and Middle East respiratory syndrome (MERS) coronavirus outbreaks in 2002/2003 and 2012 to the current situation. Overall, immunosuppressive therapy does neither seem to have a major impact on infection with SARS- and MERS-CoV nor does it seem to lead to a severe disease course in many cases. Considering the immunological responses against infections with novel coronaviruses in humans, interferons, glatiramer acetate, and teriflunomide appear to be safe. As lymphopenia seems to be associated with a more severe disease course, all DMTs causing lymphopenia, such as cladribine, alemtuzumab, and dimethyl fumarate, need to be reviewed more thoroughly. As they are, in general, associated with a higher risk of infection, depleting anti-CD20 antibodies may be problematic drugs. However, it has to be differentiated between the depletion phase and the phase of immune reconstitution. In summary, previous coronavirus outbreaks have not shown an increased risk for immunocompromised patients. Patients with severe neuroimmunological diseases should be kept from hasty discontinuation of immunotherapy."],"journal":"Front Immunol","authors":["Mohn, Nora","Pul, Refik","Kleinschnitz, Christoph","Pruss, Harald","Witte, Torsten","Stangel, Martin","Skripuletz, Thomas"],"date":"2020-06-02T11:00:00Z","year":2020,"_id":"32477373","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.3389/fimmu.2020.01059","keywords":["covid-19","dmts","mers","sars","immunosuppressive therapy","multiple sclerosis"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1668437835081842688,"score":96.59342},{"pmid":32476597,"title":"COVID-19 and Long-Term Care Policy for Older People in Hong Kong.","text":["COVID-19 and Long-Term Care Policy for Older People in Hong Kong.","Hong Kong is a major international travel hub and a densely populated city geographically adjacent to Mainland China. Despite these risk factors, it has managed to contain the COVID-19 epidemic without a total lockdown of the city. Three months on since the outbreak, the city reported slightly more than 1,000 infected people, only four deaths and no infection in residential care homes or adult day care centers. Public health intervention and population behavioral change were credited as reasons for this success. Hong Kong's public health intervention was developed from the lessons learned during the SARS epidemic in 2003 that killed 299 people, including 57 residential care residents. This perspective summarizes Hong Kong's responses to the COVID-19 virus, with a specific focus on how the long-term care system contained the spread of COVID-19 into residential care homes and home and community-based services.","J Aging Soc Policy","Lum, Terry","Shi, Cheng","Wong, Gloria","Wong, Kayla","32476597"],"abstract":["Hong Kong is a major international travel hub and a densely populated city geographically adjacent to Mainland China. Despite these risk factors, it has managed to contain the COVID-19 epidemic without a total lockdown of the city. Three months on since the outbreak, the city reported slightly more than 1,000 infected people, only four deaths and no infection in residential care homes or adult day care centers. Public health intervention and population behavioral change were credited as reasons for this success. Hong Kong's public health intervention was developed from the lessons learned during the SARS epidemic in 2003 that killed 299 people, including 57 residential care residents. This perspective summarizes Hong Kong's responses to the COVID-19 virus, with a specific focus on how the long-term care system contained the spread of COVID-19 into residential care homes and home and community-based services."],"journal":"J Aging Soc Policy","authors":["Lum, Terry","Shi, Cheng","Wong, Gloria","Wong, Kayla"],"date":"2020-06-02T11:00:00Z","year":2020,"_id":"32476597","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.1080/08959420.2020.1773192","keywords":["covid-19","hong kong","sars","nursing homes","public health interventions"],"locations":["China","China","Hong Kong's","Hong Kong's","China"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Prevention"],"weight":1,"_version_":1668437835034656769,"score":96.16342}]}